SymBio Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
SymBio Pharmaceuticals has a total shareholder equity of ¥7.0B and total debt of ¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ¥7.7B and ¥719.0M respectively.
Key information
0%
Debt to equity ratio
JP¥0
Debt
| Interest coverage ratio | n/a |
| Cash | JP¥6.55b |
| Equity | JP¥7.00b |
| Total liabilities | JP¥719.00m |
| Total assets | JP¥7.72b |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: 4582's short term assets (¥7.6B) exceed its short term liabilities (¥714.0M).
Long Term Liabilities: 4582's short term assets (¥7.6B) exceed its long term liabilities (¥5.0M).
Debt to Equity History and Analysis
Debt Level: 4582 is debt free.
Reducing Debt: 4582 had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if 4582 has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 4582 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.